Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin
- PMID: 1902076
Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin
Abstract
Adjuvant perioperative liver infusion chemotherapy with fluorouracil, mitomycin and heparin caused mild but significant myelosuppression in the first two postoperative weeks. This was associated with a slightly increased bleeding tendency. Mortality was not increased. Future trials might combine chemotherapy with hematopoietic growth factors in order to minimize myelosuppression.
Similar articles
-
Adjuvant chemotherapy for colon and rectal cancer.Semin Oncol. 1995 Oct;22(5):472-87. Semin Oncol. 1995. PMID: 7570058 Review. No abstract available.
-
[Intra-portal chemoprevention and therapy of liver metastases].Z Gastroenterol Verh. 1989 Jul;24:189-91. Z Gastroenterol Verh. 1989. PMID: 2474948 Clinical Trial. German. No abstract available.
-
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.Recent Results Cancer Res. 1986;100:157-62. doi: 10.1007/978-3-642-82635-1_20. Recent Results Cancer Res. 1986. PMID: 3755539 No abstract available.
-
Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Swiss Group for Clinical Cancer Research.Anticancer Res. 1995 Sep-Oct;15(5B):2197-200. Anticancer Res. 1995. PMID: 8572624 Clinical Trial.
-
Hepatic artery ligation or embolization and locoregional chemotherapy of liver metastases from colorectal cancer.Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2351-4. Gan To Kagaku Ryoho. 1988. PMID: 3137873 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical